^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    AKT3 mutation

    i
    Other names: AKT3, PKBG, PRKBG, RAC-gamma, V-akt murine thymoma viral oncogene homolog 3
    Entrez ID:
    10000
    Related biomarkers:
    Expression
    Mutation
    12ms
    AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations (clinicaltrials.gov)
    P1; Active, not recruiting --> Completed | Trial completion date: Oct 2023 --> May 2023 | Trial primary completion date: Oct 2023 --> May 2023
    Trial completion date • Trial primary completion date • Trial completion
    |
    AKT2 (V-akt murine thymoma viral oncogene homolog 2)
    |
    AKT3 mutation
    |
    MSK-IMPACT
    |
    Xtandi (enzalutamide capsule) • fulvestrant • Truqap (capivasertib)
    almost2years
    AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations (clinicaltrials.gov)
    P1; Trial completion date: Oct 2022 --> Oct 2023 | Trial primary completion date: Oct 2022 --> Oct 2023
    Trial completion date • Trial primary completion date
    |
    AKT2 (V-akt murine thymoma viral oncogene homolog 2)
    |
    AKT3 mutation
    |
    MSK-IMPACT
    |
    Xtandi (enzalutamide capsule) • fulvestrant • Truqap (capivasertib)
    almost2years
    AKT inhibition in the central nervous system induces signaling defects resulting in psychiatric symptomatology. (PubMed, Cell Biosci)
    Our data elucidate the incidence and mechanisms of psychiatric AEs in patients treated with PI3K/AKT/mTOR inhibitors and emphasize the need for careful monitoring.
    Journal
    |
    AKT3 (V-akt murine thymoma viral oncogene homolog 3)
    |
    AKT1 mutation • AKT3 mutation
    |
    rupitasertib (DIACC3010)
    almost3years
    AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations (clinicaltrials.gov)
    P1; Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Oct 2021 --> Oct 2022
    Trial completion date • Trial primary completion date • Clinical
    |
    AKT2 (V-akt murine thymoma viral oncogene homolog 2)
    |
    AKT3 mutation
    |
    MSK-IMPACT
    |
    Xtandi (enzalutamide capsule) • fulvestrant • Truqap (capivasertib)
    3years
    Characterization of AKT Somatic Mutations in Chinese Breast Cancer Patients. (PubMed, Cancer Manag Res)
    Patients in the GDPH cohort had lower rates of AKT and AKT3 mutation and higher AKT1 mutation rate than those in the TCGA cohort, while harboring missense mutations detected predominantly as E17K mutation in AKT1. In GDPH cohort, there were correlations between AKT mutation and the clinicopathological characteristics of patients.
    Clinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • AKT1 (V-akt murine thymoma viral oncogene homolog 1)
    |
    HER-2 expression • AKT1 mutation • ER overexpression • AKT3 E17K • AKT3 mutation